INDICATIONS

Repatha® is indicated:

  • In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization... READ MORE
  • Resources for Patient Access and Support

    Materials for Your Office

    • Getting Patients Started on Repatha®

      Specialist Consultation Referral Form

      This form collects the information required to refer patients for consultation with a specialist in the initiation of Repatha® therapy for insurance and coverage purposes.

    • Patient Education

      Repatha® Interactive Flipchart

      Interactive resources about cholesterol, CV disease and risk factors. Learn about the role of Repatha® as a treatment option, and what to expect when taking Repatha® (evolocumab).

      Repatha® Co-Pay Card Brochure

      This informational guide to the Repatha® Co-Pay Card includes program details, eligibility criteria, and how to get started.

    • CODING

      ICD-10 Coding Booklet

      This resource provides an easy-to-use guide to the ICD-10 codes relevant to Repatha®.

      FDA National Drug Code
      Directory

      Medicare ICD-10 Coding

      AMA guidance
      on telemedicine coding

      Medicare telemedicine
      healthcare provider fact sheet

    • ACCESS AND REIMBURSEMENT

      Helping Patients Start and Stay on Repatha®

      A guide to help you and your office staff help patients start and stay on Repatha®, including where to find tools, resources, prior authorization support, ICD-10 codes, and Co-Pay card information.

      Repatha® Sample Letter of Medical Necessity

      This sample letter is a template to explain the clinical rationale for prescribing Repatha®. This should accompany a prior authorization.

      Repatha® Sample Appeals Letter

      This sample letter is a template to explain the clinical rationale for prescribing Repatha®. This can be used during the appeals process.

      Physician Patient Documentation Checklist

      This checklist can organize specific information about patients’ diagnosis and treatment history to help complete a prior authorization.

      Repatha® Coverage & Affordability Brochure

      This brochure provides an overview of the increasing access and affordability of Repatha® over the years.

    Information for Patients

    • REPATHA® ONBOARDING

      Repatha® Patient Onboarding

      Resources for patients starting on Repatha® including how to fill a Repatha® prescription, what to expect, and injection information. Hear directly from Repatha® patients and their experience with treatment.

      Repatha® Patient Brochure

      A resource designed to help patients learn more about treatment with Repatha®.

    • Repatha® Financial Assistance

      Repatha® Co-Pay Card for eligible commercial patients

      Download a Co-Pay card guide for complete program information or click the button below to learn more.

    • INJECTION SUPPORT

      Every-2-Week Repatha® SureClick® Autoinjector

      Watch a video on how to inject with the Repatha® SureClick® Device (140 mg/mL single-dose prefilled autoinjector).

      Repatha® SureClick®
      Instructions for Use

      Once-a-Month Repatha®
      Pushtronex® System

      Watch a video on how to inject with the Repatha® Pushtronex® Device (420 mg/3.5 mL single-dose on-body infusor with prefilled cartridge).

      Repatha® Pushtronex® Instructions
      for Use

      Repatha® Prefilled Syringe
      Instructions for Use

      Quick Reference Guide for
      Injection

    NRx, new prescription; PCSK9, proprotein convertase subtilisin/kexin type 9; PCSK9i proprotein convertase subtilisin/kexin type 9 inhibitor.

    Important Safety Information

    Contraindications: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

    Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

    Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

    From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

    Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

    Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

    Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

    Indications

    Repatha® is indicated:

    • In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization.
    • As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C.

    Please see full Prescribing Information.